This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2008 by McGill University.
Recruitment status was:  Recruiting
Information provided by:
McGill University Identifier:
First received: September 30, 2008
Last updated: October 17, 2008
Last verified: October 2008

This is a phase IB/II trial of sorafenib, a new tyrosine kinase inhibition of multiple genes that is active against renal cancer, plus vinorelbine, a chemotherapy agent active in breast cancer.

The investigators are combining these 2 drugs in order to determine if the investigators can increase the activity of vinorelbine in metastatic breast cancer patients.

Patients with measurable metastatic breast cancer without previous chemotherapy for metastatic disease are eligible for the protocol. They will be treated with 2 different dose levels of sorafenib in order to determine the most tolerable dose.

Condition Intervention Phase
Metastatic Breast Cancer Drug: Sorafenib and Vinorelbine Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IB/II Trial of Combination of Vinorelbine With Sorafenib (BAY 43-9006) as First-Line Treatment in Patients With Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by McGill University:

Primary Outcome Measures:
  • Confirmed complete response (CR) or partial response (PR), defined according to RECIST criteria, persisting 4 weeks after the initial documentation.

Estimated Enrollment: 36
Study Start Date: October 2007
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sorafenib and Vinorelbine Drug: Sorafenib and Vinorelbine

vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);

sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe.

Other Name: BAY 43-9006


Ages Eligible for Study:   19 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women affected by histologically proven metastatic breast cancer.
  • Tumor not susceptible to therapy with trastuzumab, defined as FISH negative for HER-2 amplification or immunohistochemistry 0-1+ for HER-2 expression.
  • Female, age ≥ 18.
  • Documented measurable disease by appropriate radiologic imaging according to RECIST criteria (see Appendix E). Lesions in previously irradiated areas are not considered measurable disease, unless progression has been documented post-radiation.
  • ECOG performance status 0-1 (see Appendix B)
  • Life expectancy > 6 months.
  • Adequate bone marrow function, as indicated by:

    • Hemoglobin ≥ 90 g/L
    • Neutrophils ≥ 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
  • Adequate renal function, as indicated by serum creatinine ≤1.5 times the upper limit of normal and/or Creatinine Clearance calculated as >50% lower normal limit, or estimated as ≥ 50 ml/min (Appendix C).
  • Adequate liver function, as indicated by:

    • bilirubin ≤ 1.5 times upper normal limit;
    • AST and ALT ≤ 2 times upper normal limit.
  • Left ventricular ejection fraction (LVEF) ≥50% as measured by either multigated acquisition (MUGA) scan or echocardiogram (ECHO).
  • No therapy for breast cancer in the 4 weeks preceding the therapy start.
  • Women of childbearing potential must be using adequate contraception and have a negative pregnancy test at the time of enrollment.
  • Patient able to understand and give written informed consent.

Exclusion Criteria:

  • Patients with locally advanced breast cancer or stage IIIb only.
  • Presence of only non-measurable disease.
  • Previous (neo)adjuvant chemotherapy with vinorelbine.
  • Any previous anti-angiogenic therapy.
  • Any previous chemotherapy for metastatic breast cancer. Previous hormonal treatments or radiotherapy for metastatic disease are allowed.
  • Radiotherapy, chemotherapy or hormonal therapy for breast cancer in the last 4 weeks prior to starting the study treatment.
  • Major surgery within 4 weeks of first study treatment, or minor surgery (including placement of an access device) within 7 days of therapy start.
  • Presence of life-threatening disease or central nervous system localizations.
  • Evidence of HER-2 positive breast cancer, defined as FISH-positive for amplification or score 3+ by immunohistochemistry.
  • Any other possibly active primary tumor, except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
  • Clinically significant hepatic disease with respect to hepatitis B, hepatitis C, cirrhosis or other liver diseases.
  • Uncontrolled bacterial, viral or fungal infection.
  • Previous history of ischemic disease.
  • Patients with previous history of thrombo-embolic events, or with documented risk factors for thrombotic disease other than cancer.
  • History of gross hemorrhage within the past 6 months (e.g., hemoptysis or hematuria requiring medical intervention).
  • Uncontrolled hypertension.
  • Other serious medical conditions, such as uncontrolled cardiac disease, severe pulmonary disease, uncontrolled diabetes.
  • Patient exhibiting confusion or disorientation.
  • Any condition (medical, social, psychological, geographical) that would prevent adequate follow-up.
  • Patient is pregnant, or is breast-feeding, or is unwilling to use adequate contraception.
  • Failure to give informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00764972

Contact: Lawrence Panasci 514-340-8248
Contact: Cristiano Ferrario 514-340-8248

Canada, Quebec
Jewish General Hospital Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Lawrence Panasci    514-340-8248   
Contact: Cristiano Ferrario    514-340-8248   
Principal Investigator: Lawrence Panasci         
Sponsors and Collaborators
McGill University
Principal Investigator: Lawrence Panasci McGill University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Cristina Attard, BSc Oncology Project Specialist, Bayer HealthCare Pharmaceuticals Identifier: NCT00764972     History of Changes
Other Study ID Numbers: McG 0713
Study First Received: September 30, 2008
Last Updated: October 17, 2008

Keywords provided by McGill University:
To evaluate the use of sorafenib added to vinorelbine chemotherapy, to find out which are the doses of two drugs can be safely combined

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators processed this record on September 21, 2017